Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
03:27pm, Sunday, 14'th Dec 2025
Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their
Forget Teladoc and Buy This Healthcare Stock Instead
06:53am, Saturday, 13'th Dec 2025
Teladoc and Pfizer have both faced challenges over the past few years. While the latter has a clear path to recovery, the former doesn't seem to.
Market Today: Tech Slumps, Broadcom Tanks; EU Eases ICE Ban
05:35pm, Friday, 12'th Dec 2025
Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
01:51pm, Friday, 12'th Dec 2025
FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.
Pfizer Declares First-Quarter 2026 Dividend
12:00pm, Friday, 12'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to hol
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.
11:32am, Friday, 12'th Dec 2025
Pfizer's coronavirus-related sales have fallen sharply -- and they may decline even further next year. The company is developing some promising products, including a flu vaccine and a weight loss ther
The Best Turnaround Stock to Invest $1,000 in Right Now
10:15am, Friday, 12'th Dec 2025
Bristol Myers Squibb's stock is down 35% from its 2022 highs as it faces patent cliffs. Pfizer is down 55% from its 2021 highs as it contends with similar challenges.
Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends
08:45am, Friday, 12'th Dec 2025
The Dividend Harvesting Portfolio remains up 32.60% on invested capital, yielding 8.02%, despite a temporary dip in dividend income from the MSTY reverse split. A dovish Fed rate cut and bullish GDP p
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial
07:24am, Friday, 12'th Dec 2025
Pfizer's Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive metastatic breast cancer who had responded well to initial treatment, according to
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?
02:03pm, Thursday, 11'th Dec 2025
Investors watching the global biotech race may be sensing a shift after Moderna (MRNA) co-founder and chairman Noubar Afeyan suggested the US could be losing mo
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
06:46pm, Wednesday, 10'th Dec 2025
The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports
11:38am, Wednesday, 10'th Dec 2025
Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
08:46am, Wednesday, 10'th Dec 2025
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
08:35am, Wednesday, 10'th Dec 2025
JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigatio
